Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Corcept Therapeutics Incorporated stock | $21.6

Learn how to easily invest in Corcept Therapeutics Incorporated stock.

Corcept Therapeutics Incorporated
NASDAQ: CORT - USD
BIOTECHNOLOGY
$20.29
-$0.11 (-0.54%)

Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated shares (CORT) are listed on the NASDAQ and all prices are listed in US Dollars. Corcept Therapeutics Incorporated employs 236 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Corcept Therapeutics Incorporated

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CORT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Corcept Therapeutics Incorporated stock price (NASDAQ: CORT)

Use our graph to track the performance of CORT stocks over time.

Corcept Therapeutics Incorporated shares at a glance

Information last updated 2021-07-23.
Latest market close$21.60
52-week range$12.20 - $31.18
50-day moving average $21.82
200-day moving average $24.13
Wall St. target price$25.75
PE ratio 26.0513
Dividend yield N/A (0%)
Earnings per share (TTM) $0.78

Buy Corcept Therapeutics Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corcept Therapeutics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corcept Therapeutics Incorporated price performance over time

Historical closes compared with the close of $21.6 from 2021-05-28

1 week (2021-07-18) N/A
1 month (2021-06-29) -2.88%
3 months (2021-04-29) -7.93%
6 months (2021-01-25) N/A
1 year (2020-07-25) N/A
2 years (2019-07-25) N/A
3 years (2018-07-25) N/A
5 years (2016-07-25) N/A

Is Corcept Therapeutics Incorporated under- or over-valued?

Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Corcept Therapeutics Incorporated's P/E ratio

Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Corcept Therapeutics Incorporated shares trade at around 26x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Corcept Therapeutics Incorporated's PEG ratio

Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Corcept Therapeutics Incorporated's EBITDA

Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $110.7 million.

The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.

Corcept Therapeutics Incorporated financials

Revenue TTM $340.1 million
Operating margin TTM 32.38%
Gross profit TTM $348.3 million
Return on assets TTM 13.8%
Return on equity TTM 21.6%
Profit margin 29.23%
Book value $4.39
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting Corcept Therapeutics Incorporated shares

There are currently 8.1 million Corcept Therapeutics Incorporated shares held short by investors – that's known as Corcept Therapeutics Incorporated's "short interest". This figure is 18.5% down from 9.9 million last month.

There are a few different ways that this level of interest in shorting Corcept Therapeutics Incorporated shares can be evaluated.

Corcept Therapeutics Incorporated's "short interest ratio" (SIR)

Corcept Therapeutics Incorporated's "short interest ratio" (SIR) is the quantity of Corcept Therapeutics Incorporated shares currently shorted divided by the average quantity of Corcept Therapeutics Incorporated shares traded daily (recently around 660261.47540984). Corcept Therapeutics Incorporated's SIR currently stands at 12.2. In other words for every 100,000 Corcept Therapeutics Incorporated shares traded daily on the market, roughly 12200 shares are currently held short.

However Corcept Therapeutics Incorporated's short interest can also be evaluated against the total number of Corcept Therapeutics Incorporated shares, or, against the total number of tradable Corcept Therapeutics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corcept Therapeutics Incorporated's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Corcept Therapeutics Incorporated shares in existence, roughly 70 shares are currently held short) or 0.083% of the tradable shares (for every 100,000 tradable Corcept Therapeutics Incorporated shares, roughly 83 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Corcept Therapeutics Incorporated.

Find out more about how you can short Corcept Therapeutics Incorporated stock.

Corcept Therapeutics Incorporated share dividends

We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.

Corcept Therapeutics Incorporated share price volatility

Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $12.2 up to $31.18. A popular way to gauge a stock's volatility is its "beta".

CORT.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.7084. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).

Corcept Therapeutics Incorporated overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California. .

Frequently asked questions

What percentage of Corcept Therapeutics Incorporated is owned by insiders or institutions?
Currently 9.854% of Corcept Therapeutics Incorporated shares are held by insiders and 71.404% by institutions.
How many people work for Corcept Therapeutics Incorporated?
Latest data suggests 236 work at Corcept Therapeutics Incorporated.
When does the fiscal year end for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated's fiscal year ends in December.
Where is Corcept Therapeutics Incorporated based?
Corcept Therapeutics Incorporated's address is: 149 Commonwealth Drive, Menlo Park, CA, United States, 94025
What is Corcept Therapeutics Incorporated's ISIN number?
Corcept Therapeutics Incorporated's international securities identification number is: US2183521028
What is Corcept Therapeutics Incorporated's CUSIP number?
Corcept Therapeutics Incorporated's Committee on Uniform Securities Identification Procedures number is: 218352102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site